Isolated nail psoriasis may be a sign of psoriatic arthritis

Published Date: 02 Mar 2023

In a review of 87 patients, the authors recorded the clinical and histological characteristics of patients with nail psoriasis.

Read Full News

Latest News

FDA Approves First Oral Drug for Dermatomyositis in Adults

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

Early Step-Down Safe, Cost-Effective in Stable Candidiasis

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

China Approves J&J Psoriasis Pill Icotyde, Says Drugmaker

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar Lichen Sclerosus Affects 1 in 700 US Women

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib Controls Skin Disease in Dermatomyositis

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

Todays Updates

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Todays Updates

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Latest News

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

News All Time

FDA Staff Unconvinced Drug for Melanoma Shows Benefit

Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting

Fauci's Diaries Released; Cold Brew Recalled; Carly Simon's Diagnosis

Health news and commentary gathered by MedPage Today staff

What Is the 'Barbie Peptide' and Why Is It Risky?

Dermatologists weigh in on the injectable trend

Twice-Rejected Melanoma Drug Gets Love From FDA Panel

Vote at odds with FDA reviewers

Make the Diagnosis: She’s Losing Her Scalp and Eyebrow Hair. Why?

A 51-year-old woman visited her doctor for asymptomatic hair loss on her scalp and eyebrows that she first noticed approximately 5 months prior. Can you diagnose the patient?

FDA Finally OKs Twice-Rejected Melanoma Drug

Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy

'Carrot Maxxing' Is a New Name for an Old Trend

Eating lots of carrots can change the color of the skin, but satisfaction may vary

Tanning Is Getting Hot Again. Here's What It Really Does to Your Skin.

Tanning misinformation abounds online

Pebbled Skin and Excessive Hair Growth on a 5-Year-Old's Back

Just two of the multiple symptoms that began to emerge shortly after birth

Can 'Ferritin Face' Signal Underlying Anemia? Hematologists Weigh In

Patients attribute dull skin, brittle hair, and dark under-eye circles to ferritin deficiency

JAK Inhibitor Might Be the Most Effective One Yet for Severe Alopecia

Trials suggest more hair growth with upadacitinib in teens and adults than previously seen

Flight Attendants, Pilots Have Highest Risk of Dying From Radiation-Linked Cancers

Radiation exposure is greater for people flying at high altitudes

4 Deaths Linked to Medical Device; New FDA Chief? Human-Chimp Hybrid Attempt

Health news and commentary gathered by MedPage Today staff

How Much of a Cancer Drug Is Too Much? Some Are Challenging FDA-Approved Dosages.

— Smaller doses of some drugs could save billions and prevent some of the worst side effects

US FDA Approves Regeneron's Rare Bone Disorder Drug

Aug 19 - The U.S. FDA on Wednesday approved Regeneron's drug for a rare genetic disorder ⁠after it significantly reduced abnormal bone formation in certain soft...

Ebola Spreading Exponentially in Congo as Death Toll Tops 2,500, UN Says

More than 2,500 people have now died in the Democratic Republic of Congo's Ebola outbreak, which is spreading exponentially in an area larger ⁠than France, senior United...

Recommended News For You

Patients face high out-of-pocket costs after incident cancer diagnosis

Which Risk Model Better Identifies High-Risk Smoldering MM?

Is Vitamin D a Key to Better Breast Cancer Survival?

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.

New First-Line Option for Advanced ALK-Positive Lung Cancer

Recommended Articles For You

The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies 

Precision Erythropoietic Modeling for Hematologic Disorders 

Critical Care Updates on Critical Illness Management in Patients Receiving Active Cancer Care 

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alzheimer's Blood Test Gets FDA Clearance

2.

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

3.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

4.

New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy

5.

AI tool identifies women at high risk of interval breast cancer

1.

Personalized Survivorship Navigation in Precision Cancer Care

2.

The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition

3.

Evolution of Cancer Care Through Developmental Therapeutics

4.

Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments

5.

Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Clinical Insights in Oncology

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Breast Cancer Awareness and Early Detection

4.

Understanding Anemia: Causes and Treatment

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot